FCMI
RCUS icon

Foresite Capital Management III’s Arcus Biosciences RCUS Stock Holding History

Foresite Capital Management III’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,366,973
Closed -$10.9M – 16
2019
Q2 		$10.9M Hold
1,366,973
– – 3.56% 12
2019
Q1 		$17.1M Sell
1,366,973
-661,903
-33% -$7.18M 4.44% 7
2018
Q4 		$21.9M Sell
2,028,876
-1,416,585
-41% -$16.5M 7.18% 5
2018
Q3 		$48M Hold
3,445,461
– – 10.6% 4
2018
Q2 		$42.2M Hold
3,445,461
– – 9.08% 4
2018
Q1 		$42.1M Buy
+3,445,461
New +$57.4M 9.17% 2

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Foresite Capital Management III's RCUS Position: Q3 2019 in Review

Foresite Capital Management III sold out of Arcus Biosciences (RCUS) in Q3 2019, closing a stake of 1,366,973 shares — an estimated $10.9M sold.

Foresite Capital Management III first reported a position in RCUS in Q1 2018 and held it in 6 quarters. The position peaked at $48M in Q3 2018. 75 funds tracked by Wall St. Rank hold RCUS as of Q3 2019.

  • Foresite Capital Management III reported no remaining Arcus Biosciences position as of Q3 2019 after selling out during the quarter.
  • Foresite Capital Management III sold 1,366,973 Arcus Biosciences shares in Q3 2019, an estimated $10.9M.
  • Foresite Capital Management III first reported a position in Arcus Biosciences in Q1 2018 and held it in 6 quarters.
  • Foresite Capital Management III's Arcus Biosciences position peaked at $48M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2019.

Based on Foresite Capital Management III's 13F filing for Q3 2019, filed 13 Nov 2019.